Risk of secondary hemorrhage; conjugated estrogen · people with traumatic hyphema
Other pharmaceutical agents showed no clear difference in risk of secondary hemorrhage; conjugated estrogen compared with placebo or other control interventions (moderate certainty).
1 finding from 1 review
Risk of secondary hemorrhage; cycloplegics · people with traumatic hyphema
It is very uncertain whether other pharmaceutical agents changes risk of secondary hemorrhage; cycloplegics compared with placebo or other control interventions (very low certainty).
1 finding from 1 review
Risk of secondary hemorrhage; aspirin · people with traumatic hyphema
Other pharmaceutical agents showed no clear difference in risk of secondary hemorrhage; aspirin compared with placebo or other control interventions (low certainty).
1 finding from 1 review
Mean intraocular pressure · children at or before five years of age with primary congenital glaucoma
1 finding from 1 review
Proportion of participants with IOP≤ 21 mmHg, with or without ocular hypotensive medications 1 year · children at or before five years of age with primary congenital glaucoma
It is very uncertain whether combined trabeculotomy with trabeculectomy changes surgical success: proportion with postoperative IOP ≤ 21 mmHg with… compared with trabeculotomy (very low certainty).
1 finding from 1 review
Adverse outcomes Up to 3 years · children at or before five years of age with primary congenital glaucoma
It is very uncertain whether combined trabeculotomy with trabeculectomy changes adverse outcomes Up to 3 years compared with trabeculotomy (very low certainty).
1 finding from 1 review
Mean IOP ( · children at or before five years of age with primary congenital glaucoma
1 finding from 1 review
Proportion with postoperative IOP ≤ 21 mmHg (surgical success) with or without glaucoma medications 6 months after surgery · children at or before five years of age with primary congenital glaucoma
It is very uncertain whether viscotrabeculotomy changes proportion with postoperative IOP ≤ 21 mmHg (surgical success) with… compared with conventional trabeculotomy (very low certainty).
1 finding from 1 review
Hyphema · children at or before five years of age with primary congenital glaucoma
Viscotrabeculotomy showed no clear difference in adverse outcomes—hyphema Up to 6 months after surgery compared with conventional trabeculotomy (low certainty).
1 finding from 1 review
Mean IOP ( · children at or before five years of age with primary congenital glaucoma
1 finding from 1 review
Proportion of participants with IOP≤ 21 mmHg, with or without ocular hypotensive medications 1 year · children at or before five years of age with primary congenital glaucoma
Microcatheter‐assisted trabeculotomy probably leads to higher proportion with postoperative IOP ≤ 21 mmHg (surgical success) with… compared with conventional trabeculotomy (moderate certainty).
1 finding from 1 review
Hyphema · children at or before five years of age with primary congenital glaucoma
Microcatheter‐assisted trabeculotomy probably leads to higher adverse outcomes— hyphema Up to 1 year after surgery compared with conventional trabeculotomy (moderate certainty).
1 finding from 1 review
Proportion of participants attending screening (median · patients with type 1 or 2 diabetes eligible for diabetic retinopathy screening
1 finding from 1 review
Ongoing adherence to screening · patients with type 1 or 2 diabetes eligible for diabetic retinopathy screening
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Economic Outcomes Resources used (staff time, equipment, consumables) · patients with type 1 or 2 diabetes eligible for diabetic retinopathy screening
1 finding from 1 review
Staff/personnel costs; costs of treatment and care; cost of primary care; lost wages and lost productivity · patients with type 1 or 2 diabetes eligible for diabetic retinopathy screening
1 finding from 1 review
Proportion of participants attending screening (median · patients with type 1 or 2 diabetes eligible for diabetic retinopathy screening
1 finding from 1 review
Ongoing adherence to screening · patients with type 1 or 2 diabetes eligible for diabetic retinopathy screening
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Economic outcomes · patients with type 1 or 2 diabetes eligible for diabetic retinopathy screening
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean change in BCVA at 1 month (logMAR) · people with acute non‐arteritic CRAO
1 finding from 1 review